CVS Health (NYSE: CVS) reported Q3 EPS of $2.21, $0.08 better than the analyst estimate of $2.13. Revenue for the quarter came in at $89.76 billion versus the consensus estimate of $88.29 billion.

GUIDANCE:

CVS Health sees FY2023 EPS of $8.50-$8.70, versus the consensus of $8.58. Revised GAAP diluted EPS guidance range to $6.37 to $6.61 from $6.53 to $6.75.

For earnings history and earnings-related data on CVS Health (CVS) click here.